Pharmafile Logo

News and Press Releases

Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies

Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin demonstrated favorable safety and...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025

Lundbeck
Iveco House Station Road Watford Hertfordshire WD17 1ET

Phesi announces AI-driven Trial Accelerator platform hits new milestone with data from 132 million patients

Latest version of Trial Accelerator™ incorporates new AI capabilities and product features to unlock a patient-centric approach to trial design and implementation 29 January 2025 -- Boston, US -- Phesi,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025

Phesi
info@phesi.com
East Lyme, Connecticut, US

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

30 January 2025 -- Espoo, Finland -- Orion Corporation and Invenra Inc, an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into...

Category: Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025

Orion
Orion Corporation Orionintie 1A, FI-02200 Espoo P.O.Box 65, FI-02101 Espoo

Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors

OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 30, 2025

Owkin
https://www.owkin.com/
14/16 Bd Poissonnière, 75009 Paris

Image Analysis Group Announces Release of DYNAMIKA V.7, their Award-Winning Cloud Platform for Clinical Trial Imaging 

DYNAMIKA V.7 has achieved the British Standards Institute (BSI) surveillance audit certification following a recent SOC II Type I compliance certification 29 January 2025 -- London, UK -- Image Analysis...

Category: Clinical Trials, Drug Discovery, Other
Posted: January 29, 2025

Image Analysis Group (IAG)
contact@ia-grp.com
2-6 Boundary Row London SE1 8HP

NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform

Findings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sample ANGLE invited to present data at EACR-Illumina webinar on 6 February...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 29, 2025

ANGLE plc
2 Occam Court, Occam Road, Surrey Research Park, Guilford, GU2 7QB

Medable Reports 80% Revenue Growth from Portfolio-Level eCOA Adoption, Sharp Increase Compared to Study-by-Study Adoption

Growing industry confidence drives shift in digital strategy for clinical trial sponsors 28 January 2025 -- California, US -- Medable Inc., a leading provider of clinical development technology, today announced 80%...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 28, 2025

Medable
media@medable.com
525 University Ave Suite A70 Palo Alto, CA 94301

WCG Launches ClinSphere™ Total Enrollment: An All-New Participant Recruitment and Retention SaaS Solution for Clinical Trials

27 January 2025 -- New Jersey, US -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the launch of ClinSphere™ Total Enrollment. This...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 28, 2025

WCG Clinical
info@wcgclinical.com
212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

Protas launches novel unified clinical trial management platform, Cantata

27 January 2025 -- London, UK -- Protas, a not-for-profit organisation transforming the design and delivery of large clinical trials, announces the launch of its unified clinical trial management platform,...

Category: Clinical Trials, Drug Discovery, Other
Posted: January 27, 2025

Protas

Pfizer’s BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with investigator’s choice of...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 25, 2025

Pfizer
235 East 42nd Street NY, NY 10017

Clinical Trial Powered by Parsortix System Provides First-in-Class Data for Novel Approach to Cancer Treatment

Parsortix system used to identify patients with highly metastatic CTC clusters for targeted treatment New treatment strategy provides ‘uncharted opportunity’ to target metastasis responsible for the vast majority of cancer...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 24, 2025

ANGLE plc
2 Occam Court, Occam Road, Surrey Research Park, Guilford, GU2 7QB

Medidata and Tigermed Renew Strategic Partnership Aimed at Accelerating Clinical Trials Globally

Extended partnership will enhance study efficiency and regulatory compliance, leveraging Medidata’s platform to improve access to new therapies 23 January 2025 -- New York, US -- Medidata, a Dassault Systèmes brand...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 23, 2025

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms Analyses identified predictors of VE303 colonization and protection from CDI recurrence Topline data for the ongoing Phase...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: January 23, 2025

Vedanta Biosciences
info@vedantabio.com
19 Blackstone Street Cambridge, MA 02139

European Commission approves LAZCLUZE®▼ (lazertinib) in combination with RYBREVANT®▼ (amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

Latest topline data from the Phase 3 MARIPOSA study shows amivantamab plus lazertinib is the first regimen to demonstrate superior overall survival benefit compared to the current standard of care...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 21, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Opella reaches study milestone for Cialis

21 January 2025 -- Paris, France -- Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual...

Category: Clinical Trials, Other, Pharmaceutical
Posted: January 21, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK